KR100992850B1 - 시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도 - Google Patents

시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도 Download PDF

Info

Publication number
KR100992850B1
KR100992850B1 KR1020047005721A KR20047005721A KR100992850B1 KR 100992850 B1 KR100992850 B1 KR 100992850B1 KR 1020047005721 A KR1020047005721 A KR 1020047005721A KR 20047005721 A KR20047005721 A KR 20047005721A KR 100992850 B1 KR100992850 B1 KR 100992850B1
Authority
KR
South Korea
Prior art keywords
delete delete
cyclosporin
mixture
isomer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047005721A
Other languages
English (en)
Korean (ko)
Other versions
KR20050037421A (ko
Inventor
셀바라즈 네이커
랜달 더블유. 야츠코프
로버트 티. 포스터
Original Assignee
이소테크니카 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이소테크니카 인코포레이티드 filed Critical 이소테크니카 인코포레이티드
Publication of KR20050037421A publication Critical patent/KR20050037421A/ko
Application granted granted Critical
Publication of KR100992850B1 publication Critical patent/KR100992850B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
KR1020047005721A 2001-10-19 2002-10-17 시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도 Expired - Lifetime KR100992850B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US60/346,201 2001-10-19

Publications (2)

Publication Number Publication Date
KR20050037421A KR20050037421A (ko) 2005-04-21
KR100992850B1 true KR100992850B1 (ko) 2010-11-09

Family

ID=23358378

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047005721A Expired - Lifetime KR100992850B1 (ko) 2001-10-19 2002-10-17 시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도

Country Status (38)

Country Link
US (2) US20110092669A1 (cg-RX-API-DMAC7.html)
EP (2) EP1436322B1 (cg-RX-API-DMAC7.html)
JP (4) JP2005511538A (cg-RX-API-DMAC7.html)
KR (1) KR100992850B1 (cg-RX-API-DMAC7.html)
CN (1) CN100344648C (cg-RX-API-DMAC7.html)
AR (1) AR036853A1 (cg-RX-API-DMAC7.html)
AT (1) ATE401339T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002331510B2 (cg-RX-API-DMAC7.html)
BE (1) BE2022C547I2 (cg-RX-API-DMAC7.html)
BR (1) BR0213659A (cg-RX-API-DMAC7.html)
CA (2) CA2727642C (cg-RX-API-DMAC7.html)
CO (1) CO5570682A2 (cg-RX-API-DMAC7.html)
CY (2) CY1108410T1 (cg-RX-API-DMAC7.html)
DE (1) DE60227686D1 (cg-RX-API-DMAC7.html)
DK (1) DK1436322T3 (cg-RX-API-DMAC7.html)
EC (3) ECSP045059A (cg-RX-API-DMAC7.html)
ES (1) ES2310604T3 (cg-RX-API-DMAC7.html)
FI (1) FIC20220041I1 (cg-RX-API-DMAC7.html)
FR (1) FR22C1051I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20040353B1 (cg-RX-API-DMAC7.html)
IL (2) IL160762A0 (cg-RX-API-DMAC7.html)
LT (1) LTC1436322I2 (cg-RX-API-DMAC7.html)
MA (1) MA26337A1 (cg-RX-API-DMAC7.html)
ME (1) ME00487B (cg-RX-API-DMAC7.html)
MX (1) MXPA04003624A (cg-RX-API-DMAC7.html)
MY (1) MY187182A (cg-RX-API-DMAC7.html)
NL (1) NL301200I2 (cg-RX-API-DMAC7.html)
NO (2) NO331745B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ531945A (cg-RX-API-DMAC7.html)
PL (1) PL210697B1 (cg-RX-API-DMAC7.html)
PT (1) PT1436322E (cg-RX-API-DMAC7.html)
PY (2) PY0225477A (cg-RX-API-DMAC7.html)
RU (1) RU2337106C2 (cg-RX-API-DMAC7.html)
SI (1) SI1436322T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN04069A1 (cg-RX-API-DMAC7.html)
UY (1) UY27502A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003033527A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200402270B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1436322T3 (da) * 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler
HRP20070058B1 (hr) 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
TW200635954A (en) * 2004-12-17 2006-10-16 Isotechnika Inc Metabolites of cyclosporin analogs
KR101273681B1 (ko) * 2005-10-26 2013-06-25 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
EP2150269B1 (en) * 2007-05-02 2012-11-21 Astellas Pharma Inc. New cyclic peptide compounds
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物
RU2361604C1 (ru) * 2007-10-29 2009-07-20 Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) Способ лечения атопического дерматита
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
EP3549051A4 (en) * 2016-11-30 2020-04-29 Schrodinger, Inc. GRAPHIC USER INTERFACE FOR CALCULATING CHEMICAL TRANSITIONAL STATES
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
US11523772B2 (en) 2016-12-14 2022-12-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US10286036B2 (en) * 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CA3172535A1 (en) * 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
EP4201952A1 (en) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Process for the controlled synthesis of voclosporin
WO2024052941A1 (en) * 2022-09-09 2024-03-14 Dr. Reddy's Laboratories Limited Improved process for the preparation of voclosporin
IT202300001056A1 (it) * 2023-01-25 2024-07-25 Procos Spa Nuovo processo per la preparazione di voclosporina amorfa
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
WO2025119925A1 (en) 2023-12-05 2025-06-12 Medichem, S.A. Process for preparing voclosporin
IT202300028041A1 (it) * 2023-12-27 2025-06-27 Indena Spa Processo per la preparazione di voclosporina

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018120A1 (en) * 1997-10-08 1999-04-15 Isotechnika Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278545A (en) * 1979-09-12 1981-07-14 The Bendix Corporation Apparatus for separating solids and liquid components
CH670644A5 (cg-RX-API-DMAC7.html) * 1986-12-18 1989-06-30 Lonza Ag
US5162540A (en) * 1986-12-18 1992-11-10 Lonza Ltd. Process for the production of (+) biotin
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
US5972630A (en) * 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
DK0869810T3 (da) * 1996-06-19 2005-02-07 Novartis Ag Cyclosporinholdige blöde kapselpræparater
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
HRP20070058B1 (hr) * 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
DK1436322T3 (da) * 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018120A1 (en) * 1997-10-08 1999-04-15 Isotechnika Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents

Also Published As

Publication number Publication date
PY0225478A (es) 2004-05-03
RU2004110941A (ru) 2005-08-10
ZA200402270B (en) 2005-05-25
FR22C1051I1 (fr) 2022-12-16
ES2310604T3 (es) 2009-01-16
KR20050037421A (ko) 2005-04-21
IL160762A0 (en) 2004-08-31
ECSP045059A (es) 2004-07-23
PL370501A1 (en) 2005-05-30
JP2009197036A (ja) 2009-09-03
ATE401339T1 (de) 2008-08-15
ECSP045060A (es) 2004-07-23
JP5272140B2 (ja) 2013-08-28
US20110092669A1 (en) 2011-04-21
NL301200I2 (nl) 2024-07-25
ME00487B (me) 2011-10-10
CA2727642A1 (en) 2003-04-24
HRP20040353B1 (hr) 2012-10-31
FR22C1051I2 (fr) 2023-11-17
AU2002331510B2 (en) 2008-05-01
EP1436322A2 (en) 2004-07-14
ECSP045061A (es) 2004-08-27
AR036853A1 (es) 2004-10-06
US20140288266A1 (en) 2014-09-25
DK1436322T3 (da) 2008-11-03
NZ531945A (en) 2006-01-27
CY2022030I1 (el) 2023-01-27
PT1436322E (pt) 2008-10-23
IL160762A (en) 2010-11-30
LTC1436322I2 (cg-RX-API-DMAC7.html) 2023-06-26
EP1816138A1 (en) 2007-08-08
CN100344648C (zh) 2007-10-24
DE60227686D1 (de) 2008-08-28
PY0225477A (es) 2004-05-03
RU2337106C2 (ru) 2008-10-27
CY2022030I2 (el) 2023-06-09
CA2460685C (en) 2014-05-27
HK1062567A1 (en) 2004-11-12
WO2003033527A3 (en) 2003-10-16
CA2727642C (en) 2014-02-04
BR0213659A (pt) 2004-10-26
HRP20040353A2 (en) 2005-04-30
BE2022C547I2 (cg-RX-API-DMAC7.html) 2022-10-19
CN1571794A (zh) 2005-01-26
CY1108410T1 (el) 2012-05-23
LTPA2022521I1 (cg-RX-API-DMAC7.html) 2022-11-10
CO5570682A2 (es) 2005-10-31
NO20042029L (no) 2004-05-14
PL210697B1 (pl) 2012-02-29
CA2460685A1 (en) 2003-04-24
JP2005511538A (ja) 2005-04-28
TNSN04069A1 (en) 2006-06-01
JP2013136597A (ja) 2013-07-11
MY187182A (en) 2021-09-08
EP1436322B1 (en) 2008-07-16
NO2022042I1 (no) 2022-10-14
SI1436322T1 (sl) 2008-12-31
WO2003033527A2 (en) 2003-04-24
MA26337A1 (fr) 2004-10-01
JP2011006417A (ja) 2011-01-13
UY27502A1 (es) 2003-04-30
FIC20220041I1 (fi) 2022-10-14
NO331745B1 (no) 2012-03-19
MXPA04003624A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
KR100982466B1 (ko) 시클로스포린 유사체의 합성
KR20050037421A (ko) 시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도
AU2002331510A1 (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
HK1062567B (en) Cyclosporine analogue mixtures and their use as immunomodulating agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040417

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070816

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090530

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090530

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20100319

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20100129

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20101026

Appeal identifier: 2010101002082

Request date: 20100319

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20100319

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20100319

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090923

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20040720

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100517

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20101026

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20100421

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20101102

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20101103

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20131016

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20131016

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20140929

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20140929

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20150930

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20150930

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20160929

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20170929

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20180928

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20190924

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210929

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20230417

Termination category: Expiration of duration